Free radical oxidation and immune status in patients with community-acquired pneumonia: efficacy of Immunovenin
https://doi.org/10.18093/0869-0189-2016-26-2-190-195
Abstract
The aim of this study was to investigate reactive oxygen species (ROS) production in the blood and the immune status of patients with community-acquired pneumonia (CAP). The second aim was to evaluate clinical efficacy of immunoglobulin agent Immunovenin in these patients. Methods. ROS level in the blood was measured using the luminol-dependent chemiluminescence. The cellular and humoral immunity, IFN-γ and FNO-α blood concentrations and blood neutrophil phagocytic activity were also assessed. Of 52 patients with CAP, 18 patients were treated with Immunovenin intravenously additionally to the standard therapy and 34 patients were treated with the standard therapy. Results. The blood chemiluminescence intensity was increased and the immune status was abnormal in patients with CAP. Administration of Immunovenin led to reduction in severity of clinical symptoms, decrease in the ROS concentration in the blood and improvement in the immunity. Conclusion. Inclusion of IV immunoglobulin in the complex therapy of CAP could improve the course of the disease and the efficacy of treatment.
About the Authors
A. M. Mirkhaydarov
State City Outpatient Clinic No.47: 33, Dagestanskaya str., Ufa, 450024, the Republic of Bashkortostan;
Russian Federation
Russian Federation
Head of Day hospital at the State City Outpatient Clinic No.47, Ufa, tel.: (8-347) 281-90-37;
U. R. Farkhutdinov
State City Clinical Hospital No.21: 3, Lesnoy passage; Ufa, 450071, the Republic of Bashkortostan;
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, the Republic of Bashkortostan
Russian Federation
Russian Federation
MD, Professor at Departmenrt of Propaedeutics of Internal Diseases, Bashkir State Medical University, Healthcare Ministry of Russia; Head of Pulmonology Department, State City Clinical Hospital No.21; tel.: (8-347) 246-53-57, fax: (347) 232-19-22;
R. R. Farkhutdinov
Bashkir State Medical University, Healthcare Ministry of Russia: 3, Lenina str., Ufa, 450000, the Republic of Bashkortostan
Russian Federation
Russian Federation
MD, Professor, Head of the Central Research Laboratory, Bashkir State Medical University, Healthcare Ministry of Russia; tel.: (8-347) 272-63-49;
References
1. Chuchalin A.G., Sinopal'nikov A.I., Kozlov R.S. et al. Community-acquired pneumonia in adults. Clinical guidelines on diagnosis, treatment and prevention. Moscow: RRO, MAKMAKh; 2010 (in Russian).
2. Woodhead M. Pneumonia. In: Palange P., Simonds A.K., eds. ERS Handbook: Respiratory Medicine. Sheffield; 2013: 199–202.
3. Chuchalin A.G., Sinopal'nikov A.I., Kozlov R.S. Clinical guidelines on diagnosis, treatment and prevention of severe community-acquired pneumonia in adults. Moscow: RRO, MAKMAKh; 2014: 68 (in Russian).
4. Chuchalin A.G. Slowly-resolving pneumonia. Terapevticheskiy arkhiv. 2015; 3: 4–9 (in Russian).
5. Savchenko A.A., Dresvyankina L.V., Grinshteyn Yu.I. et al. Neutrophil granulocyte chemoluminescent activity in patients with community-acquired pneumonia according to the course severity. Pul'monologiya. 2014; 3: 62–67 (in Russian).
6. Shoykhet Ya.N., Lepilov A.V., Motin Yu.G., Korenovskiy Yu.V. A role of oxidative injury of the lungs for development of acute lung abscess. Pul'monologiya. 2012; 1: 27–30 (in Russian).
7. Farkhutrdinov R.R., Farkhutdinov U.R., Abdrakhmanova L.M. Chemiluminescent Methods in Pulmonology: Methodological Guidelines. Ufa; 2011 (in Russian).
8. Alsynbaev M.M., Medvedev Yu.A., Tuygunov M.M. Biological agents and main direction for their therapeutic and preventive administration. Ufa; 2006 (in Russian).
9. Farkhutdinov R.R. Methods for evaluating chemiluminescence of biological species using the chemiluminometer CHL-003. In: Farkhutdinov R.R., Tevdoradze S.I. Measuring antioxidant activity of biologically active agents for therapeutic and preventive use: Collected scientific papers. Moscow: Izdatel’stvo RUDN; 2005: 147–155 (in Russian).
10. Bayramgulov F.A., Bulgakova A.D., Bikmetova N.R., Kurelenkova M.E. An experience of flow cytometry in a clinical diagnostic laboratory. Actual issues of postgraduate training of physicians and pharmaceutists. In: Novel technologies in medicine. A Regional Research and Practical Conference proceedings. Ufa; 2001: 98–99 (in Russian).
11. Mancini G., Garbonara A., Heremans G. Immunological quantitation of antigens by single radial immunodiffusion. Immunochemestry. 1965; 2 (3): 235–254.
12. Men'shikov V.V., ed. Methods of clinical and laboratory investigations. A Reference Guide. Moscow: Labora; 2009. V. 3 (in Russian).
13. Niederman M.S., Mandell L.A., Anzueto A. et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163 (7): 1730–1754.
14. Tjon A.S., van Gent R., Geijtenbeek T.B., Kwekkeboom J. Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye. Front. Immunol. 2015; 6: 197–201.
15. Matucci A., Maggi E., Vultaggio A. Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects. Front. Immunol. 2014; 5: 690.
16. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 2013; 13 (3): 176–189.
17. Kaveri S.V., Lecerf M., Saha C. et al. Intravenous immunoglobulin and immune response. Clin. Exp. Immunol. 2014; 178 (1): 94–96.
18. Tha-In T., Bayry J., Metselaar H.J. et al. Modulation of the cellular immune system by intravenous immunoglobulin. J. Trends. Immunol. 2008; 29: 608–615.
19. Sriskandan S., Ferguson M., Elliot V., et al. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. Antimicrob. Chemother. 2006; 58 (1): 117–124.
Review
For citations:
Mirkhaydarov A.M., Farkhutdinov U.R., Farkhutdinov R.R. Free radical oxidation and immune status in patients with community-acquired pneumonia: efficacy of Immunovenin. PULMONOLOGIYA. 2016;26(2):190-195. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-2-190-195
Views:
1319
Email this article 